查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081901

醫藥合約開發與生產（CDMO）市場：2026-2032年全球市場預測（依服務類型、分子類型、開發階段、溫度需求、生產模式和最終用途分類）

Pharmaceutical Contract Development & Manufacturing Market by Service Type, Molecule Type, Development Stage, Temperature Requirement, Production Mode, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，藥品合約開發和生產 (CDMO) 市場將成長至 2,657.9 億美元，複合年成長率為 8.71%。

主要市場統計數據
基準年 2025 1480.6億美元
預計年份：2026年 1602億美元
預測年份：2032年 2657.9億美元
複合年成長率 (%) 8.71%

醫藥CDMO市場市場動態概述

對於尋求縮短研發週期、穩定供應、專業化生產能力以及符合監管標準的品質系統的製藥公司而言，合約研發生產（CDMO）服務已成為一項戰略性基礎設施。這種需求主要源於生命週期管理項目，這些項目需要生物製藥、高活性原料藥、無菌注射劑、細胞和基因療法、複雜學名藥、先進製劑開發、分析方法開發、製程驗證以及商業化生產等方面的專業知識。

CDMO產業的變革性變化

供應鏈在地化、生物製藥的擴張、無菌生產的限制以及日益嚴格的監管要求正在重塑醫藥CDMO產業的格局。公共衛生危機、地緣政治風險以及基本藥物短缺迫使各國政府和贊助商重新評估對單一來源生產和長距離活性成分供應鏈的依賴。這促使人們更加關注擁有雙重來源、區域生產網路和檢驗的緊急時應對計畫的可靠CDMO合作夥伴。

人工智慧對CDMO的累積影響

人工智慧 (AI) 透過改進分子篩檢、製劑設計、製程最佳化、預測性維護、偏差檢測、需求預測和監管資訊分析，在合約藥物開發和生產的整體方面都帶來了累積的益處。在研發領域，機器學習有助於加速實驗設計並有效率地識別關鍵程式參數；當與檢驗的科學工作流程結合時，它可以幫助團隊減少批次失敗並加速技術轉移。

全球CDMO市場關鍵區域洞察

以中國、印度、日本、韓國、新加坡和澳洲為首的亞太地區仍然是藥品合約開發和生產的核心成長區域。該地區受益於大規模原料藥生產、生物製藥投資、臨床試驗活動以及政府對生命科學製造的支持。中國持續擴大其生物製藥和創新藥物的生產能力，而印度在學名藥、原料藥、疫苗和具有成本競爭力的研發服務方面仍扮演著重要角色。日本、韓國和澳洲在先進生物製藥、臨床開發、嚴格的品質標準和受監管的市場准入方面表現卓越。

CDMO策略的關鍵小組見解

隨著新加坡、馬來西亞、泰國、印尼、越南和菲律賓等國在醫藥價值鏈中參與度的不斷加深，東協正崛起為務實的醫藥製造和臨床供應中心。新加坡憑藉其生物製造能力、成熟的監管體系和區域總部活動脫穎而出，而其他東協成員國則提供成本效益高的生產、不斷成長的醫療保健需求以及日益完善的工業基礎設施。對於合約研發生產企業（CDMO）而言，該地區支持「中國+1」採購模式、區域包裝、臨床供應物流和打入市場策略。

醫藥CDMO關鍵國家洞察

美國是創新驅動型合約研發生產（CDMO）需求的中心，這得益於FDA監管的研發、生物製藥產品線、創業投資投資支持的生物技術、孤兒藥活動以及關鍵藥物回流的獎勵。加拿大提供專業的研發、臨床主導和完善的生物技術生態系統。另一方面，墨西哥的優勢在接近性美國市場、成熟的生產能力以及對近岸藥品供應日益成長的興趣。巴西是拉丁美洲最大的藥品市場，其國內需求、公共衛生領域的採購、對生物相似藥的興趣以及監管現代化都為製造外包提供了支持。

CDMO領導者使用的實用建議

產業供應商應優先考慮穩健的生產力計畫，在成本效益與雙重來源、地理多元化和檢驗的業務永續營運之間取得平衡。合約研發生產機構（CDMO）應投資於高需求能力，例如無菌填充和包裝、生技藥品、抗體藥物偶聯物（ADC）、高活性藥物、分析服務和低溫運輸包裝。申辦方在評估合作夥伴時，不僅應考慮價格，還應考慮其檢查記錄、技術轉移成熟度、批次成功率、資料完整性、監管文件品質和可擴展性。

調查方法和證據

本執行摘要系統地整合了公開的監管指南、行業資訊披露、政府生產政策、藥品貿易趨勢、檢查重點以及公認的品質框架。主要參考資料包括美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 的監管預期、國際人用藥品註冊技術協調會 (ICH) 指南、世界衛生組織 (WHO) 的生產和准入重點、國家生命科學戰略、公開的生產能力公告以及小分子藥物外包生物製藥、無菌產品、疫苗和先進療法等領域的申辦和先進療法。

結論：醫藥CDMO的策略展望

醫藥合約研發生產（CDMO）市場正步入一個更具策略性的時代，其特徵是科學複雜性、產能限制、品質要求和供應鏈韌性。該市場正從傳統的外包模式轉向跨越全球和區域網路的一體化夥伴關係，以支持加速研發、滿足監管要求並提高商業性可靠性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：醫藥合約開發與生產組織（CDMO）市場：依服務類型分類

  • 合約開發服務
    • 分析與發展
    • 臨床診斷試劑的生產
    • 配方開發
    • 製程開發
  • 契約製造服務
    • 活性藥物成分（API）的生產
    • 成品製造（FDF）
    • 包裝服務

第8章：藥品合約開發與生產組織（CDMO）市場：依分子類型分類

  • 低分子化合物
  • 生物製劑
  • 胜肽
  • 寡核苷酸
  • 細胞療法
  • 基因治療

第9章：醫藥合約開發與生產（CDMO）市場：依開發階段分類

  • 臨床階段
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業
  • 臨床前階段

第10章：藥品合約開發與生產組織 (CDMO) 市場：依溫度要求分類

  • 室溫
  • 冷藏
  • 冰凍
  • 極低溫度

第11章：藥品合約開發與生產（CDMO）市場：依生產方式分類

  • 大量生產
  • 連續製造

第12章：醫藥合約開發與生產組織（CDMO）市場：依最終用途分類

  • 心血管系統
  • 中樞神經系統
  • 感染疾病
  • 腫瘤學

第13章：醫藥合約開發與生產組織（CDMO）市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：醫藥合約開發與生產組織（CDMO）市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：藥品合約開發與生產組織（CDMO）市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie, Inc.
  • Aenova Holding GmbH
  • Almac Group
  • Amgen Inc.
  • Baxter International Inc.
  • Biozoc Inc.
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Curia Global, Inc.
  • Danaher Corporation
  • Dr. Reddy's Laboratories Ltd.
  • Elkos Group
  • Evonik Industries AG
  • Famar Group
  • Fareva Group
  • Jubilant Pharma Limited
  • Kryptochem Medicament Pvt. Ltd.
  • Lonza Group
  • Midas Pharma GmbH
  • Nipro Group
  • Novartis AG
  • Pfizer Inc.
  • Pidolma Healthcare
  • PYRAMID Laboratories, Inc.
  • Recipharm AB
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • WuXi AppTec Co., Ltd
Product Code: MRR-4316E4E8930E

The Pharmaceutical Contract Development & Manufacturing Market is projected to grow by USD 265.79 billion at a CAGR of 8.71% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 148.06 billion
Estimated Year [2026] USD 160.20 billion
Forecast Year [2032] USD 265.79 billion
CAGR (%) 8.71%

Executive Introduction to Pharmaceutical CDMO Market Dynamics

Pharmaceutical contract development and manufacturing organizations (CDMOs) have become strategic infrastructure for drug sponsors seeking faster development timelines, resilient supply, specialized manufacturing capacity, and regulatory-grade quality systems. Demand is being shaped by biologics, high-potency active pharmaceutical ingredients, sterile injectables, cell and gene therapies, complex generics, and lifecycle management programs that require advanced formulation, analytical development, process validation, and commercial-scale manufacturing expertise.

The sector is moving beyond transactional outsourcing toward integrated development and manufacturing partnerships. Sponsors are prioritizing CDMOs with proven regulatory inspection histories, scalable capacity, disciplined technology transfer, data integrity controls, and the ability to support quality-by-design, continuous improvement, and global market access. This executive summary evaluates pharmaceutical CDMO market dynamics through regional, group, and country-level lenses while addressing the compounding role of artificial intelligence in pharmaceutical development and manufacturing.

Transformative Shifts in the CDMO Landscape

The pharmaceutical CDMO landscape is being reshaped by supply chain localization, biologics expansion, sterile manufacturing constraints, and heightened regulatory expectations. Public health disruptions, geopolitical risk, and shortages of essential medicines have pushed governments and sponsors to reassess dependence on single-source manufacturing and long-distance active pharmaceutical ingredient supply chains. This is increasing interest in dual sourcing, regional manufacturing networks, and trusted CDMO partners with validated contingency planning.

Scientific complexity is also changing outsourcing criteria. More pipelines now involve large molecules, antibody-drug conjugates, mRNA platforms, peptides, highly potent compounds, and patient-specific therapies. These modalities demand containment infrastructure, aseptic fill-finish capability, advanced analytics, cold-chain readiness, and specialist talent. As a result, competitive advantage is shifting toward CDMOs that can integrate development, clinical manufacturing, regulatory documentation, and commercial production under robust quality management systems.

Cumulative Impact of Artificial Intelligence on CDMOs

Artificial intelligence is creating cumulative gains across pharmaceutical contract development and manufacturing by improving molecule screening, formulation design, process optimization, predictive maintenance, deviation detection, demand forecasting, and regulatory intelligence. In development settings, machine learning supports faster experimental design and more efficient identification of critical process parameters, helping teams reduce failed batches and accelerate technology transfer when combined with validated scientific workflows.

In manufacturing, AI-enabled analytics strengthen real-time monitoring, equipment utilization, and quality risk management. However, adoption is constrained by data quality, model validation, cybersecurity, and regulatory expectations for explainability, validation, and human oversight. CDMOs that align AI deployment with FDA, EMA, ICH Q9(R1), ICH Q10, ICH Q13, and data integrity principles are better positioned to convert automation and advanced analytics into measurable operational reliability rather than isolated digital pilots.

Key Regional Insights Across Global CDMO Markets

Asia-Pacific remains a core growth region for pharmaceutical contract development and manufacturing, led by China, India, Japan, South Korea, Singapore, and Australia. The region benefits from API scale, biologics investment, clinical trial activity, and government support for life sciences manufacturing. China continues to expand biologics and innovative drug manufacturing capacity, while India remains critical for generics, APIs, vaccines, and cost-competitive development services. Japan, South Korea, and Australia add strength in advanced biologics, clinical development, stringent quality expectations, and regulated market access.

North America is defined by high-value innovation, FDA-regulated manufacturing, biologics capacity, sterile injectables, and strong sponsor demand for quality-certified outsourcing. The United States remains the anchor market, while Canada and Mexico support clinical, manufacturing, and nearshoring strategies. Latin America, led by Brazil and Mexico, is gaining relevance through local access needs, public health procurement, and regional supply diversification. Europe is shaped by EMA standards, advanced pharmaceutical clusters, sustainability requirements, serialization, and specialized manufacturing across Germany, France, Italy, Spain, the United Kingdom, Ireland, Belgium, and the Nordics. The Middle East is investing in pharmaceutical self-sufficiency through Saudi Arabia and the United Arab Emirates, with emphasis on local production and medicine security, while Africa's opportunity is tied to vaccine manufacturing, essential medicines, technology transfer, and public-private capacity building aligned with health security priorities.

Key Group Insights for CDMO Strategy

ASEAN is emerging as a practical manufacturing and clinical supply hub as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines deepen participation in pharmaceutical value chains. Singapore stands out for biomanufacturing, regulatory maturity, and regional headquarters activity, while other ASEAN members offer cost-efficient production, expanding healthcare demand, and improving industrial infrastructure. For CDMOs, the group supports China-plus-one sourcing, regional packaging, clinical supply logistics, and market access strategies.

The GCC is prioritizing medicine security, local production, and healthcare industrialization, especially in Saudi Arabia and the United Arab Emirates, where national health and industrial strategies are encouraging pharmaceutical localization. The European Union remains one of the world's most regulated and technologically advanced pharmaceutical manufacturing blocs, with strong demand for GMP compliance, sustainability, serialization, pharmacovigilance readiness, and specialized production. BRICS countries are influential because they combine large populations, expanding healthcare systems, API scale, and domestic manufacturing policy. G7 markets drive premium outsourcing demand through innovation intensity, mature regulatory systems, and high-value biologics and advanced therapy pipelines, while NATO-aligned supply chain planning increasingly influences procurement resilience for critical medicines, emergency preparedness, and strategic health security.

Key Country Insights for Pharmaceutical CDMOs

The United States is the leading innovation-driven CDMO demand center, supported by FDA-regulated development, biologics pipelines, venture-backed biotechnology, orphan drug activity, and reshoring incentives for critical medicines. Canada contributes specialized research, clinical manufacturing, and a supportive biotechnology ecosystem, while Mexico benefits from proximity to the U.S. market, established manufacturing capabilities, and growing interest in nearshore pharmaceutical supply. Brazil is Latin America's principal pharmaceutical market, with domestic demand, public health procurement, biosimilar interest, and regulatory modernization supporting outsourced manufacturing opportunities.

In Europe, the United Kingdom remains strong in biotech innovation, clinical development, and advanced therapies. Germany is a major hub for pharmaceutical engineering, biologics, and high-quality manufacturing, while France supports vaccines, biologics, and policy-backed industrial renewal. Italy and Spain are established centers for contract manufacturing, sterile products, and pharmaceutical exports, and Russia remains focused on domestic production under import substitution policy. In Asia-Pacific, China offers large-scale development and biologics capacity, India anchors APIs, generics, vaccines, and cost-efficient CDMO services, Japan demands high-quality specialized manufacturing and strong compliance discipline, Australia supports clinical-stage development and early-phase trial activity, and South Korea has built globally competitive biologics manufacturing capacity supported by advanced infrastructure and policy focus.

Actionable Recommendations for CDMO Leaders

Industry vendors should prioritize resilient capacity planning by balancing cost efficiency with dual sourcing, geographic diversification, and validated business continuity. CDMOs should invest in high-demand capabilities including sterile fill-finish, biologics, antibody-drug conjugates, high-potency manufacturing, analytical services, and cold-chain-ready packaging. Sponsors should evaluate partners using inspection performance, technology transfer maturity, batch success rates, data integrity, regulatory documentation quality, and scalability rather than price alone.

Vendors should also build AI and automation roadmaps tied to measurable quality and productivity outcomes. Recommended priorities include digital batch records, predictive maintenance, advanced process control, deviation analytics, secure data platforms, and validated model governance. To sustain differentiation, CDMOs should strengthen talent pipelines, align with ICH quality standards, improve environmental performance, and create transparent governance models for long-term sponsor partnerships.

Research Methodology and Evidence Base

This executive summary is based on a structured synthesis of public regulatory guidance, industry disclosures, government manufacturing policies, pharmaceutical trade patterns, inspection priorities, and recognized quality frameworks. Core reference points include FDA and EMA regulatory expectations, ICH guidelines, WHO manufacturing and access priorities, national life sciences strategies, publicly available capacity announcements, and observed sponsor outsourcing behavior across small molecules, biologics, sterile products, vaccines, and advanced therapies.

The methodology applies triangulation across demand-side indicators, supply-side capacity signals, regional policy developments, regulatory requirements, and technology adoption trends. Insights are evaluated through market relevance, regulatory credibility, manufacturing feasibility, and strategic importance to pharmaceutical sponsors and CDMOs. The analysis avoids unsupported projections and focuses on verifiable, decision-useful patterns shaping pharmaceutical contract development and manufacturing competitiveness.

Conclusion: Strategic Outlook for Pharmaceutical CDMOs

Pharmaceutical contract development and manufacturing is entering a more strategic era defined by scientific complexity, capacity constraints, quality expectations, and supply chain resilience. The market is expanding from conventional outsourcing into integrated partnerships that support development acceleration, regulatory readiness, and commercial reliability across global and regional networks.

CDMOs that combine specialized infrastructure, regulatory excellence, digital maturity, and geographic flexibility will be best positioned to capture growth. Sponsors that select partners through a risk-adjusted lens can improve speed, compliance, and supply continuity while navigating a more complex pharmaceutical manufacturing environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmaceutical Contract Development & Manufacturing Market, by Service Type

  • 7.1. Contract Development Services
    • 7.1.1. Analytical Development
    • 7.1.2. Clinical Trial Material Manufacturing
    • 7.1.3. Drug Formulation Development
    • 7.1.4. Process Development
  • 7.2. Contract Manufacturing Services
    • 7.2.1. Active Pharmaceutical Ingredient (API) Manufacturing
    • 7.2.2. Finished Dosage Form (FDF) Manufacturing
    • 7.2.3. Packaging Services

8. Pharmaceutical Contract Development & Manufacturing Market, by Molecule Type

  • 8.1. Small Molecules
  • 8.2. Biologics
  • 8.3. Peptides
  • 8.4. Oligonucleotides
  • 8.5. Cell Therapies
  • 8.6. Gene Therapies

9. Pharmaceutical Contract Development & Manufacturing Market, by Development Stage

  • 9.1. Clinical
    • 9.1.1. Phase I
    • 9.1.2. Phase II
    • 9.1.3. Phase III
  • 9.2. Commercial
  • 9.3. Preclinical

10. Pharmaceutical Contract Development & Manufacturing Market, by Temperature Requirement

  • 10.1. Ambient
  • 10.2. Refrigerated
  • 10.3. Frozen
  • 10.4. Cryogenic

11. Pharmaceutical Contract Development & Manufacturing Market, by Production Mode

  • 11.1. Batch Manufacturing
  • 11.2. Continuous Manufacturing

12. Pharmaceutical Contract Development & Manufacturing Market, by End Use

  • 12.1. Cardiovascular
  • 12.2. Central Nervous System
  • 12.3. Infectious Diseases
  • 12.4. Oncology

13. Pharmaceutical Contract Development & Manufacturing Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Pharmaceutical Contract Development & Manufacturing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pharmaceutical Contract Development & Manufacturing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie, Inc.
  • 17.2. Aenova Holding GmbH
  • 17.3. Almac Group
  • 17.4. Amgen Inc.
  • 17.5. Baxter International Inc.
  • 17.6. Biozoc Inc.
  • 17.7. Boehringer Ingelheim International GmbH
  • 17.8. Cambrex Corporation
  • 17.9. Catalent, Inc.
  • 17.10. Curia Global, Inc.
  • 17.11. Danaher Corporation
  • 17.12. Dr. Reddy's Laboratories Ltd.
  • 17.13. Elkos Group
  • 17.14. Evonik Industries AG
  • 17.15. Famar Group
  • 17.16. Fareva Group
  • 17.17. Jubilant Pharma Limited
  • 17.18. Kryptochem Medicament Pvt. Ltd.
  • 17.19. Lonza Group
  • 17.20. Midas Pharma GmbH
  • 17.21. Nipro Group
  • 17.22. Novartis AG
  • 17.23. Pfizer Inc.
  • 17.24. Pidolma Healthcare
  • 17.25. PYRAMID Laboratories, Inc.
  • 17.26. Recipharm AB
  • 17.27. Siegfried Holding AG
  • 17.28. Thermo Fisher Scientific Inc.
  • 17.29. Vetter Pharma-Fertigung GmbH & Co. KG
  • 17.30. WuXi AppTec Co., Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL TRIAL MATERIAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL TRIAL MATERIAL MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL TRIAL MATERIAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG FORMULATION DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG FORMULATION DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG FORMULATION DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FINISHED DOSAGE FORM (FDF) MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FINISHED DOSAGE FORM (FDF) MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FINISHED DOSAGE FORM (FDF) MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PACKAGING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PACKAGING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PACKAGING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OLIGONUCLEOTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OLIGONUCLEOTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMMERCIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMMERCIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMMERCIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AMBIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AMBIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AMBIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL REFRIGERATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL REFRIGERATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL REFRIGERATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FROZEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FROZEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FROZEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CRYOGENIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRYOGENIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CRYOGENIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BATCH MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BATCH MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BATCH MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 180. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 181. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 207. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 210. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 211. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 220. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 221. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 222. NATO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 247. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 248. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 254. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 260. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 261. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 262. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 277. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TEMPERATURE REQUIREMENT, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRODUCTION MODE, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 284. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 288. FRANCE PHARMACEUTICAL